Considering post-neoadjuvant strategies, first data come from the Capecitabine for Residual Cancer as Adjuvant Therapy (CREATE-X) (9), a randomized phase III trial enrolling patients with stage I-III, HER2 negative breast cancer not achieving a pathological complete response to neoadjuvant treatment. Here, ERBB2 is linked to cancer.